menu search

PODD / Insulet to Present at Upcoming Investor Conferences

Insulet to Present at Upcoming Investor Conferences
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its OmnipodĀ® brand of products, today announced that management will present at two upcoming investor conferences: The Raymond James & Associates 44th Annual Institutional Investors Conference in Orlando, FL on Tuesday, March 7, 2023 at 9:15 a.m. Read More
Posted: Feb 14 2023, 06:00
Author Name: Business Wire
Views: 110660

PODD News  

Insulet (PODD) stock up 14% on positive earnings and growth forecast

By Invezz
November 3, 2023

Insulet (PODD) stock up 14% on positive earnings and growth forecast

Shares of medical device company Insulet Corporation (NASDAQ: PODD) witnessed a remarkable surge, jumping by 14% on Friday in response to the company' more_horizontal

Insulet Stock Rallies on Revenue Boost. It's a 'Misunderstood Growth Name.

By Barrons
November 3, 2023

Insulet Stock Rallies on Revenue Boost. It's a 'Misunderstood Growth Name.

The automated insulin technology developer posts third-quarter revenue of $432.7 million, compared with $340.8 million a year earlier. more_horizontal

Insulet shares rebound after results top estimates

By Market Watch
November 3, 2023

Insulet shares rebound after results top estimates

Insulet Corp. shares PODD, +1.98% climbed 10% premarket on Friday after the insulin pump maker late Thursday reported third-quarter results that beat more_horizontal

Insulet Corporation (PODD) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 2, 2023

Insulet Corporation (PODD) Q3 2023 Earnings Call Transcript

Insulet Corporation (NASDAQ:PODD ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Deborah Gordon - Vice President, more_horizontal

Insulet (PODD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

By Zacks Investment Research
November 2, 2023

Insulet (PODD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended September 2023, it could be more_horizontal

Insulet Corporation: Still No Bargain

By Seeking Alpha
October 30, 2023

Insulet Corporation: Still No Bargain

Today, we take a look at Insulet Corporation, a mid-cap medical device concern. The company is focused on developing and marketing insulin delivery sy more_horizontal

Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think

By Zacks Investment Research
October 25, 2023

Is Insulet (PODD) a Solid Growth Stock? 3 Reasons to Think "Yes"

Insulet (PODD) is well positioned to outperform the market, as it exhibits above-average growth in financials. more_horizontal

Down -20.51% in 4 Weeks, Here's Why Insulet (PODD) Looks Ripe for a Turnaround

By Zacks Investment Research
October 17, 2023

Down -20.51% in 4 Weeks, Here's Why Insulet (PODD) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Insulet (PODD) as it is technically in oversold territory now. In addition to this technical measu more_horizontal


Search within

Pages Search Results: